Patents Examined by Md. Younus Meah
  • Patent number: 9854799
    Abstract: Provided is a host cell comprising a rhlA gene or an ortholog thereof, under the control of a heterologous promoter and a rhlB gene or an ortholog thereof, under the control of a heterologous promoter. The host cell is capable of achieving a carbon yield of more than 0.18 Cmol rhamnolipid/Cmol substrate. Provided is also a method of producing rhamnolipids, employing such a host cell.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: January 2, 2018
    Assignee: Amlika Mercantile Private Limited
    Inventors: Lars Blank, Frank Rosenau, Susanne Wilhelm, Andreas Wittgens, Till Tiso
  • Patent number: 9828592
    Abstract: The present disclosure provides a sophorolipid composition that can be used for inducing protein expression in a fermentation host. The sophorolipid composition described herein can be prepared from a natural sophorolipid mixture. Acid treatment of the natural sophorolipid mixture results in a mixture of monoacetylated, deacetylated, and/or diacetylated sophorolipids. The chemically modified sophorolipid composition, or isolated components of the chemically modified sophorolipid composition, can be used as inducers for protein production in filamentous fungi.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: November 28, 2017
    Assignee: Qingdao Vland Biotech Group Co., Ltd.
    Inventor: Tom Tao Huang
  • Patent number: 9810690
    Abstract: Provided herein are compositions, reactions mixtures, mutant Ras proteins, kits, substrates, and systems for selecting a Ras antagonist, as well as methods of using the same.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: November 7, 2017
    Assignee: ARAXES PHARMA LLC
    Inventors: Matthew P. Patricelli, Ulf Peters, Liansheng Li, Pingda Ren, Yi Liu
  • Patent number: 9796964
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing 5-((4S)-2-oxo-4-phenyl (1,3-oxazolidin-3-yl))-1-(4-fluorophenyl) pentane-1,5-dione to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize the intermediate (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one in a process for making Ezetimibe.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 24, 2017
    Assignee: Codexis, Inc.
    Inventors: Emily Mundorff, Erik Jan De Vries
  • Patent number: 9796990
    Abstract: The present invention relates to enzymes capable of hydrolysing organophosphate (OP) molecules. In particular, the invention relates to variants of the OpdA enzyme from Agrobacterium that display improved activity when compared to the naturally occurring OpdA. The invention is also towards polypeptides that have organophosphate hydrolysing activity for the organophosphates chlorpyrifos methyl, diazinon and parathion ethyl.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: October 24, 2017
    Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION
    Inventors: Colin Scott, John Oakeshott, Robyn Russell, Nigel French, Steven Kotsonis, Kaiyan Liu
  • Patent number: 9790524
    Abstract: The present invention is to provide a preparation of variant recombinant whole cell biocatalysts, referred herein as “designer cells” having significantly enhanced carbonyl reductase activity for use in the efficient production of variant industrially important enantiomerically enriched alcohols. More specifically, the alcohol is optically pure ethyl (S)-4-chloro-3-hydroxybutyrate, which is useful as chiral building block and an intermediate for the production of hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: October 17, 2017
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Gautam Srivastava, Suneet Kaur, Ravinder Singh Jolly
  • Patent number: 9790305
    Abstract: The present invention is directed towards a protein-polymer composition having a protein with a site-specifically incorporated unnatural amino acid initiator and a covalently attached polymer.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 17, 2017
    Assignee: Franklin and Marshall College
    Inventors: Ryan A. Mehl, Krzysztof Matyjaszewski, Saadyah Averick
  • Patent number: 9764077
    Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: September 19, 2017
    Assignee: EXTHERA MEDICAL CORPORATION
    Inventors: Olle Larm, Tomas Bergstrom
  • Patent number: 9758777
    Abstract: The present invention relates to the production of sugar hydrolysates from cellulosic material. The method may be used e.g. for producing fermentable sugars for the production of bioethanol from lignocellulosic material. Cellulolytic enzymes and their production by recombinant technology is described, as well as uses of the enzymes and enzyme preparations.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: September 12, 2017
    Assignee: Roal OY
    Inventors: Jari Vehmaanperä, Marika Alapuranen, Terhi Puranen, Matti Siika-Aho, Jarno Kallio, Satu Hooman, Sanni Voutilainen, Teemu Halonen, Liisa Viikari
  • Patent number: 9719072
    Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. A polynucleotide encoding a peroxygenase was isolated from Thielavia hyrcaniae.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: August 1, 2017
    Assignee: Novozymes A/S
    Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
  • Patent number: 9714439
    Abstract: The present disclosure relates to the use of an amino acid dehydrogenase in combination with a cofactor regenerating system comprising a ketoreductase. In particular embodiments, the process can be used to prepare L-tert-leucine using a leucine dehydrogenase.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: July 25, 2017
    Assignee: Codexis, Inc.
    Inventors: Fabien Louis Cabirol, Steven J. Collier, Thomas Daussmann, Naga K. Modukuru
  • Patent number: 9708632
    Abstract: A non-naturally occurring microbial organism includes a microbial organism having a 1,3-butanediol (1,3-BDO) pathway having at least one exogenous nucleic acid encoding a 1,3-BDO pathway enzyme expressed in a sufficient amount to produce 1,3-BDO.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: July 18, 2017
    Assignee: Genomatica, Inc.
    Inventors: Anthony P. Burgard, Mark J. Burk, Robin E. Osterhout, Priti Pharkya
  • Patent number: 9708588
    Abstract: The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: July 18, 2017
    Assignee: Codexis, Inc.
    Inventors: Jovana Nazor, Derek J. Smith, Michael A. Crowe, Shiwei Song, Steven J. Collier
  • Patent number: 9650612
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: May 16, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
  • Patent number: 9644189
    Abstract: The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: May 9, 2017
    Assignee: Codexis, Inc.
    Inventors: Michael A. Crowe, Oscar Alvizo, Behnaz Behrouzian, Yong Koy Bong, Steven J. Collier, Anupam Gohel, Jagadeesh Mavinahalli, Naga K. Modukuru, Emily Mundorff, Derek J. Smith, Shiwei Song, Wan Lin Yeo
  • Patent number: 9617568
    Abstract: The disclosure relates to engineered enone reductase polypeptides having improved properties, polynucleotides encoding the engineered polypeptides, related vectors, host cells, and methods for making the engineered enone reductase polypeptides. The disclosure also provides methods of using the engineered enone reductase polypeptides for chemical transformations.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 11, 2017
    Assignee: Codexis, Inc.
    Inventors: Christopher K. Savile, Vesna Mitchell, Xiyun Zhang, Gjalt W. Huisman
  • Patent number: 9617573
    Abstract: The present disclosure provides engineered transaminase polypeptides useful for the synthesis of chiral amine compounds under industrially relevant conditions. The disclosure also provides polynucleotides encoding the engineered transaminase polypeptides, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases for the production of chiral amine compounds.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: April 11, 2017
    Assignee: Codexis, Inc.
    Inventors: Martina Quintanar-Audelo, Ellen Eberhard, Jovana Nazor, Derek Smith, Cuixia Wang
  • Patent number: 9598685
    Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; SI 20 IV; or combinations thereof. Specific combination mutations include E1 191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S 1199Y, or E 1191 Q and S 1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 21, 2017
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson
  • Patent number: 9592279
    Abstract: An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: March 14, 2017
    Assignees: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, SEIKAGAKU CORPORATION
    Inventors: Yukihiro Matsuyama, Kenji Kadomatsu, Shiro Imagama, Akiomi Tanaka
  • Patent number: 9567617
    Abstract: What is aimed at is provision of an inexpensive and efficient saccharification method for lignocellulose using a thermostable xylanase and provision of a mutant xylanase that has a substitute amino acid residue, and that exhibits stable activity even under severe conditions in which enzymes easily inactivate, and that provides an initial rate of reaction not significantly reduced as compared to a wild-type xylanase corresponding to the mutant xylanase. Provided is a method of producing a saccharified product of lignocellulose, including contacting a lignocellulosic raw material with a thermostable xylanase, and a mutant xylanase that provides an initial rate of reaction that is at least 70% of that provided by a wild-type xylanase corresponding thereto, that has a xylanase activity after heat treatment at 50° C. for 24 hours that is at least 50% of its xylanase activity before the heat treatment, and that has a substitute amino acid residue.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: February 14, 2017
    Assignees: MITSUI CHEMICALS, INC., MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Hisaaki Yanai, Hiroki Tamai, Masami Osabe, Fumikazu Yokoyama, Kaoru Okakura, Atsushi Inoue